Cite
HARVARD Citation
Merrill, J. et al. (n.d.). FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Annals of the rheumatic diseases. pp. 761-762. [Online].